How Testosterone Cypionate Affects Free Testosterone Levels

Testosterone Cypionate Raises Free Testosterone: Direction and Magnitude

Free testosterone increases reliably when men with hypogonadism begin testosterone cypionate injections. The rise is not simply proportional to total testosterone because SHBG binding capacity becomes partially saturated, leaving a larger unbound fraction circulating in plasma. In the Testosterone Trials (TTrials, N=790), men aged 65 and older who received transdermal testosterone (comparable pharmacodynamics to cypionate at steady state) raised their median total testosterone from approximately 232 ng/dL to 469 ng/dL, with free testosterone climbing proportionally higher due to SHBG occupancy shifts [1].

Injectable cypionate produces even more pronounced free testosterone spikes than gels because of its bolus pharmacokinetics. A pharmacokinetic study of 200 mg intramuscular testosterone cypionate in hypogonadal men found peak total testosterone levels of 1,112 ± 297 ng/dL at 3 to 5 days post-injection, with calculated free testosterone peaking in parallel [2]. Trough values settled between 400 and 600 ng/dL by day 14, but free testosterone remained disproportionately elevated compared to pre-treatment ratios.

The Endocrine Society's 2018 clinical practice guideline states: "The goal of testosterone therapy is to raise serum testosterone to the mid-normal range for healthy young men" [3]. Free testosterone, rather than total testosterone alone, offers the more clinically meaningful measure in men with altered SHBG concentrations (obesity, aging, liver disease, thyroid disorders). A 2020 analysis in the Journal of Clinical Endocrinology & Metabolism demonstrated that free testosterone calculated by the Vermeulen equation correlated more strongly with symptom improvement than total testosterone in TRT-treated men [4].

Why Free Testosterone Rises Disproportionately on TRT

The explanation sits in SHBG biochemistry. Only 1% to 3% of circulating testosterone is free. Roughly 40% to 50% binds loosely to albumin (this albumin-bound fraction plus free testosterone constitutes "bioavailable testosterone"), and the remainder binds tightly to SHBG [5]. When exogenous testosterone enters the bloodstream, the finite number of SHBG binding sites becomes increasingly occupied. Each additional nanogram of testosterone beyond SHBG saturation flows almost entirely into the free pool.

Testosterone cypionate also suppresses hepatic SHBG synthesis. A study published in Clinical Endocrinology found that intramuscular testosterone reduced SHBG by a mean of 16% over 6 months (p<0.01), amplifying free testosterone gains beyond what the dose alone would predict [6]. This dual mechanism (saturation of existing SHBG plus reduced SHBG production) explains why men sometimes see a 3-fold rise in free testosterone from only a 2-fold rise in total testosterone.

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has noted: "Free testosterone is the hormone fraction that actually enters cells and activates the androgen receptor. Total testosterone can be misleading when SHBG is high or low" [7]. This clinical reality makes free testosterone monitoring a non-negotiable part of TRT management.

Pharmacokinetics: Time Course of Free Testosterone Changes

Testosterone cypionate has a half-life of approximately 8 days in depot oil after intramuscular injection. Free testosterone begins rising within 24 to 48 hours of the first injection and reaches meaningful clinical levels by week 3. Steady-state trough concentrations typically establish by 6 to 12 weeks of consistent dosing [8].

The injection-to-injection pattern matters. On a weekly 100 mg protocol, free testosterone peaks around day 2 to 3, then gradually declines. On a biweekly 200 mg protocol, the peak-to-trough swing is wider: free testosterone may exceed the upper reference range at the peak and approach pre-treatment levels at the trough. This sawtooth pattern is why the Endocrine Society recommends measuring testosterone at trough, specifically "midway between injections for those on a biweekly regimen, or just before the next injection for weekly protocols" [3].

A 2004 pharmacokinetic study in the Journal of Andrology detailed the time course: after a single 200 mg intramuscular dose of testosterone cypionate, serum testosterone peaked at 1 to 112 ng/dL on day 4 and declined to 400 ng/dL by day 14 [2]. Calculated free testosterone followed the same curve, peaking at approximately 35 pg/mL and declining to 12 to 15 pg/mL at trough. These values represent a 3- to 4-fold increase over the typical hypogonadal baseline free testosterone of 4 to 8 pg/mL.

How to Monitor Free Testosterone on Testosterone Cypionate

Correct timing and assay selection determine whether free testosterone results are clinically useful. Draw trough blood (the lowest point in the dosing cycle) to avoid measuring artificially inflated peak values. For weekly injections, this means drawing labs on day 6 or 7 before the next injection. For biweekly injections, draw on day 12 to 14.

The Endocrine Society's 2018 guideline recommends checking testosterone levels "3 to 6 months after initiating therapy, then annually" [3]. Initial dose titration may require more frequent checks, every 6 to 8 weeks, until the target range is established.

Assay accuracy varies significantly. Equilibrium dialysis is the gold standard for free testosterone measurement, but it is expensive and not universally available [9]. Calculated free testosterone (using measured total testosterone, SHBG, and albumin via the Vermeulen equation) provides a reliable alternative. Direct analog immunoassays for free testosterone, by contrast, are inaccurate at low concentrations and should be avoided. The American Urological Association notes: "Direct free testosterone assays lack precision and should not be used for clinical decision-making in hypogonadal men" [10].

A practical monitoring panel on testosterone cypionate includes total testosterone, free testosterone (calculated or by equilibrium dialysis), SHBG, estradiol, hematocrit, and PSA. The interplay between these analytes tells the full story. Rising SHBG (from aging, liver changes, or thyroid medication) can mask adequate total testosterone production while free testosterone remains low. Falling SHBG (from obesity or exogenous androgens) can inflate free testosterone even when the dose has not changed.

Factors That Modify Free Testosterone Response to Testosterone Cypionate

Not every patient achieves the same free testosterone increase on the same dose. Body composition, age, comorbidities, concurrent medications, and injection technique all influence the magnitude and stability of free testosterone elevation.

Body mass index. Obese men have lower SHBG at baseline, which means their pre-treatment free testosterone may be relatively preserved even when total testosterone is low. Paradoxically, these men sometimes see a smaller percentage increase in free testosterone on TRT because their SHBG is already suppressed [11]. A 2015 meta-analysis in Obesity Reviews (k=32 studies) found that men with BMI >35 required 20% to 30% higher testosterone cypionate doses to reach the same trough free testosterone as normal-weight men [12].

Age. SHBG rises approximately 1.2% per year after age 40 [5]. Older men starting TRT may see a more dramatic free testosterone response simply because their higher SHBG suppresses more under exogenous testosterone. The TTrials enrolled men 65 and older exclusively and confirmed significant free testosterone elevation with modest total testosterone increases [1].

Injection frequency. Splitting a biweekly dose into weekly injections reduces peak-to-trough variation. A study in Translational Andrology and Urology showed that weekly 75 mg injections produced 40% less peak-to-trough free testosterone fluctuation compared to biweekly 150 mg injections, with equivalent mean levels [13]. Many clinicians now prefer weekly or even subcutaneous twice-weekly protocols to minimize symptom cycling.

Concurrent medications. Aromatase inhibitors (anastrozole, for example) reduce estradiol conversion and can indirectly raise free testosterone by preventing estrogenic upregulation of SHBG. Thyroid hormone replacement raises SHBG, potentially blunting free testosterone gains unless the cypionate dose is adjusted [14].

Clinical Significance: When Free Testosterone Matters More Than Total

Several clinical scenarios make free testosterone the primary metric for dose adjustment. In men with elevated SHBG (common with aging, hepatitis C treatment, anticonvulsants, or hyperthyroidism), total testosterone can appear normal while free testosterone remains in the hypogonadal range. Treating to a total testosterone target alone would leave these patients under-dosed and symptomatic.

Conversely, in men with low SHBG (obesity, metabolic syndrome, type 2 diabetes, nephrotic syndrome), total testosterone may look low while free testosterone is adequate. Prescribing or increasing testosterone cypionate based on total testosterone alone risks supraphysiologic free testosterone levels and associated side effects: polycythemia, acne, sleep apnea worsening, and mood disturbance [3].

A 2019 study in European Urology found that symptom resolution (libido, energy, mood) correlated more tightly with free testosterone normalization (r=0.61) than with total testosterone normalization (r=0.38) in 305 men on TRT for primary or secondary hypogonadism [15]. The clinical takeaway is direct: titrate to free testosterone, not total testosterone alone, and verify that trough free testosterone sits within 15 to 25 pg/mL by equilibrium dialysis or calculated equivalent.

Target Ranges and Dose Titration Using Free Testosterone

Most reference laboratories report free testosterone ranges for adult men as 5.0 to 21.0 pg/mL (equilibrium dialysis) or 47 to 244 pg/mL (calculated). The target on TRT is generally the mid-to-upper half of the reference range. The Endocrine Society suggests aiming for testosterone concentrations "in the mid-normal range," which, for free testosterone by equilibrium dialysis, corresponds to roughly 15 to 25 pg/mL [3].

Dose adjustments follow a structured approach. If trough free testosterone is below target, increase the weekly dose by 25 mg and recheck in 6 to 8 weeks. If trough free testosterone exceeds the upper limit, reduce the dose by 25 mg. If free testosterone is on target but symptoms persist, evaluate estradiol, sleep, thyroid function, and mood disorders before attributing the problem to testosterone dosing.

The American Association of Clinical Endocrinologists (AACE) recommends a starting dose of testosterone cypionate at 75 to 100 mg intramuscular weekly, with titration guided by trough free testosterone and clinical response [16]. Starting at the lower end reduces the risk of erythrocytosis (hematocrit >54%), which occurs in approximately 5% to 14% of men on TRT according to a meta-analysis of 15 randomized trials published in JAMA Internal Medicine [17].

Safety Monitoring Alongside Free Testosterone

Free testosterone monitoring does not exist in isolation. Clinicians should concurrently track hematocrit (goal <54%), PSA (obtain baseline and recheck at 3 to 6 months, then annually), estradiol, and lipid profiles. The TTrials found no significant increase in cardiovascular events over 12 months but did note a statistically significant increase in coronary artery plaque volume in the testosterone group versus placebo (p=0.003) [18]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided larger-scale reassurance: testosterone replacement did not increase the incidence of major adverse cardiovascular events compared with placebo (hazard ratio 0.99; 95% CI 0.81 to 1.21) [19].

Monitoring free testosterone alongside hematocrit creates a safety feedback loop. If free testosterone is in range but hematocrit rises above 50%, consider dose reduction, therapeutic phlebotomy, or switching to a transdermal formulation that produces lower peak levels and less erythropoietic stimulation.

Prescribers should also counsel patients that free testosterone values obtained from different laboratories using different assays are not directly comparable. Patients should use the same laboratory for serial monitoring whenever possible.